Eric Dishman, a vice president of Intel's health and life sciences organization, is leaving the company for a position with the federal Precision Medicine Initiative Cohort Program, according to The Oregonian.
Mr. Dishman will work with the National Institutes of Health to lead a study of the impact of precision medicine.
Mr. Dishman survived a rare form of kidney cancer and credits precision medicine as the reason his treatment plan was successful, according to the report.